Mostrar el registro sencillo del ítem
An azole tolerant endosomal trafficking mutant of Candida albicans is susceptible to azole treatment in a mouse model of vaginal candidiasis.
dc.contributor.author | Peters, Brian M. | spa |
dc.contributor.author | Luna Tapia, Arturo | spa |
dc.contributor.author | Tournu, Héléne | spa |
dc.contributor.author | Rybak, Jeffrey M. | spa |
dc.contributor.author | Rogers, David P. | spa |
dc.contributor.author | Palmer, Glen E. | spa |
dc.coverage.spatial | Colombia | spa |
dc.date.accessioned | 2019-09-24T22:14:35Z | spa |
dc.date.available | 2019-09-24T22:14:35Z | spa |
dc.date.issued | 2019-09-24 | spa |
dc.identifier.citation | Peters, B.M., Luna, A., Tournu, H., Rybak, J.M., Rogers, P.D. & Palmer, G.E. (2017). An azole tolerant endosomal trafficking mutant of Candida albicans is susceptible to azole treatment in a mouse model of vaginal candidiasis. Antimicrobial Agents and Chemotherapy . 61(6). | spa |
dc.identifier.issn | 1098-6596 | spa |
dc.identifier.uri | https://repositorio.unisucre.edu.co/handle/001/792 | spa |
dc.description | Artículo digital. | spa |
dc.description.abstract | We recently reported that a Candida albicans endosomal trafficking mutant continues to grow after treatment with the azole antifungals. Herein, we report that the vps21Δ/Δ mutant does not have a survival advantage over wild-type isolates after fluconazole treatment in a mouse model of vaginal candidiasis. Furthermore, loss of VPS21 does not synergize with established mechanisms of azole resistance, such as overexpression of efflux pumps or of Erg11p, the target enzyme of the azoles. In summary, although loss of VPS21 function enhances C. albicans survival after azole treatment in vitro, it does not seem to affect azole susceptibility in vivo. | eng |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Estados Unidos Antimicrobial Agents and Chemotherapy, 2017. | spa |
dc.relation.ispartof | Articulo de revista | spa |
dc.rights | Derechos Reservados - Universidad de Sucre, 2019 | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | spa |
dc.source | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444139/ | spa |
dc.title | An azole tolerant endosomal trafficking mutant of Candida albicans is susceptible to azole treatment in a mouse model of vaginal candidiasis. | spa |
dc.type | Artículo de revista | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.type.driver | info:eu-repo/semantics/article | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
dc.identifier.doi | 10.1128/AAC.00084-17 | spa |
dc.relation.references | White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41:1482–1487. | spa |
dc.relation.references | Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143: 405–416. https://doi.org/10.1099/00221287-143-2-405. | spa |
dc.relation.references | Goldway M, Teff D, Schmidt R, Oppenheim AB, Koltin Y. 1995. Multidrug resistance in Candida albicans: disruption of the BENr gene. Antimicrob Agents Chemother 39:422– 426. https://doi.org/10.1128/ AAC.39.2.422. | spa |
dc.relation.references | Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676 –2684. https://doi.org/10.1128/AAC.45.10.2676-2684.2001. | spa |
dc.relation.references | White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46:1704 –1713. https://doi.org/10.1128/AAC.46.6.1704-1713.2002. | spa |
dc.rights.creativecommons | Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) | spa |
dc.subject.proposal | Azoles | spa |
dc.subject.proposal | Candida albicans | spa |
dc.subject.proposal | Resistance | spa |
dc.subject.proposal | Tolerance | spa |
dc.subject.proposal | Vaginal candidiasis | spa |
dc.subject.proposal | Vps21p | spa |
dc.contributor.corporatename | American Society for Microbiology. | spa |
dc.type.content | Text | spa |
dc.type.redcol | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |